January 27, 2026 — Leads & Copy — Tempus AI, Inc. has announced findings from a new study indicating that its Immune Profile Score (IPS) algorithm more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) compared to conventional biomarkers such as tumor mutational burden (TMB), microsatellite instability (MSI), and PD-L1.
IPS is a biomarker that utilizes DNA and RNA analysis, combining clinical and immune-related biomarkers to predict a patient’s response to ICI-based therapy. The results demonstrate that IPS consistently outperforms conventional biomarkers. In four independent validation cohorts of pan-cancer metastatic solid organ cancer patients, IPS was a more accurate predictor of ICI outcomes (HR=0.45) than TMB, MSS, and PD-L1, demonstrating prognostic utility that is independent of those conventional biomarkers.
The study identified 13% of patients with microsatellite stable colorectal cancer who demonstrated overall survival with ICI treatment (HR=0.2), suggesting ICI immunotherapy could be a viable option for a patient population that might have been overlooked with conventional biomarkers alone.
Beyond colorectal cancer, IPS classified 17% of patients with rare metastatic solid tumors as “IPS-High,” despite these patients not falling within a cancer-specific FDA-approved ICI label. The difference in median real-world overall survival in “IPS High” versus “IPS-Low” patients (HR=0.26) shows that ICI could be a relevant and potentially life-saving option for patients that might otherwise be missed.
“This study builds on previous findings showing that IPS scoring can identify patients who may have better overall survival with ICI therapy,” said Halla Nimeiri, MD, Chief Development Officer at Tempus. “By leveraging a multimodal algorithm, our IPS test provides a more accurate and comprehensive view than traditional, independent biomarkers, empowering physicians to make more confident treatment decisions for their patients while simultaneously moving the field forward in meaningful ways.”
The test is available as an add-on for clinicians ordering Tempus’ xT (DNA) and xR (RNA) assays.
Tempus is a technology company advancing precision medicine through the application of artificial intelligence in healthcare. The company says it provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
For more information, visit tempus.com.
Source: Tempus
